BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ortec International Inc. (ORTN.OB) And HAPTO Biotech Ltd. Announce Positive Results With Biologically Active Biomaterial Applicable To Cosmetic Tissue Augmentation And Wound Healing Markets


10/19/2005 5:09:51 PM

NEW YORK--(BUSINESS WIRE)--May 23, 2005--Ortec International, Inc. (ORTN) and HAPTO Biotech, Inc. (HAPTO) announced positive pre-clinical in vivo results generated through their joint venture. The joint venture was established to combine Ortec's and HAPTO's respective technologies to develop a non cellular biologically active enhanced collagen biomaterial to promote the attraction and attachment of healthy cells for application to the wound healing, reconstructive, cosmetic, orthopedic, tissue regeneration and dental markets. The results of the animal study, which are expected to be published shortly, showed that Ortec's proprietary collagen sponge scaffold, modified by attachment of HAPTO's proprietary peptides ("Haptides") that promote cell adhesion, had a higher cell binding potential than standard, untreated collagen. A histological analysis of sub-dermal implants of modified collagen discs in rats indicated that at day 8, collagen sponges treated with the Haptides exhibited greater stability, attracted more skin fibroblasts (30% greater), and resulted in enhanced new collagen deposition with reduced inflammatory reaction when compared to the standard collagen implant control.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES